FORMULATION ARTICLES
-
![Genetic engineering-GettyImages-1133966737]( "The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs")
The Great Cell Therapy Reset: Solving The Industrial Math Of Living DrugsThe cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).
-
![Genetic engineering, dna-GettyImages-1310083278]( "Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next")
Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes NextOligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.
-
![RNA strands, SiRNA, mRNA, CRISPR delivery-GettyImages-2151198841]( "In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors")
In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid TumorsBy injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.
-
![cancer cell screening, disease treatment medical-GettyImages-2189938556]( "Powering Cell Therapies With RNA: A New Code For Engineered Immunity")
Powering Cell Therapies With RNA: A New Code For Engineered ImmunityRNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.
-
![digital exchange, money transfer-GettyImages-2148127398]( "Why RNA Tech Transfer Is So Hard — And How the Field Can Fix It")
Why RNA Tech Transfer Is So Hard — And How the Field Can Fix ItA closer look at why RNA tech transfer remains one of the field’s toughest bottlenecks — and the practical steps developers and CDMOs can take to finally streamline the path to GMP.
-
![GettyImages-1128195910-vial-white-powder-lyophilization]( "Four Reasons You Should Choose Lyophilization for Your Next Project")
Four Reasons You Should Choose Lyophilization for Your Next ProjectLyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.
FORMULATION VIDEOS
CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.
In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.
While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.
Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2151198847-lipid-nanoparticle-with-rna-strands]( "Advancing Cell Therapies With Lipid Nanoparticles")
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
![Pharmaceutical-Drug-Manufacturing-GettyImages-1405788565]( "Nanoparticle Engineering Addresses The Challenge Of Poor Aqueous Solubility")
As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.
-
![GettyImages-1287846309-research-lab-computer-graph-data]( "Low-Volume Production For Screening High-Value Nanoparticle Materials")
A platform that harnesses microfluidic mixing has been demonstrated as a simple, robust, and scalable production method for LNPs encapsulating various types of nucleic acids.
-
![GettyImages-1317697233-cancer-t-cells]( "A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy")
We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.
-
![Doctor Preparing Injection Site GettyImages-1379313214]( "How LNP Technology Meets The Delivery Need Of saRNA Vaccines")
Explore challenges to the successful development of RNA-based drugs and vaccines as well as the advantages of utilizing lipid nanoparticle technology as a delivery platform for saRNA.
-
![Treatment with Nanoparticles Genetic therapy GettyImages-805434264]( "Process Development Considerations For RNA-LNP Therapeutics")
Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).
-
![RNA abbreviation of ribonucleic acid-GettyImages-1453953422]( "Navigating Challenges In Progressing Breakthrough RNA Therapeutics")
RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.
